NMRA Neumora Therapeutics
- 9.900
- +0.210+2.17%
- 9.900
- 0.0000.00%
Neumora Therapeutics News
This Neumora Therapeutics Insider Increased Their Holding In The Last Year
Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression
Potential to alleviate unmet need associated with depressed mood and anhedonia in bipolar depression; navacaprant has demonstrated the ability to improve these symptoms in MDD in a Phase 2 study Navacaprant is also
Neumora Therapeutics, Inc. (NMRA) Gets a Buy From Bank of America Securities
Analysts Are Bullish on These Healthcare Stocks: Neumora Therapeutics, Inc. (NMRA), IDEAYA Biosciences (IDYA)
Neumora Therapeutics | 10-Q: Quarterly report
Neumora Therapeutics 1Q Loss/Shr 34c >NMRA
Neumora Therapeutics 1Q Loss/Shr 34c >NMRA
Neumora Therapeutics Reports Q1 Cash, Cash Equivalents And Marketable Securities Of $423M, Which Is Expected To Support Operations Into 2026
Neumora Therapeutics Reports Q1 Cash, Cash Equivalents And Marketable Securities Of $423M, Which Is Expected To Support Operations Into 2026
Neumora Therapeutics Q1 2024 GAAP EPS $(0.34), Inline
Neumora Therapeutics (NASDAQ:NMRA) reported quarterly losses of $(0.34) per share which met the analyst consensus estimate.
Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
On-track to report topline Phase 3 data from KOASTAL-1 study with navacaprant in MDD; guidance narrowed to fourth quarter of 2024 Multiple clinical study initiations planned in second quarter of 2024,
Neumora Therapeutics to Participate in Upcoming Conferences in May
WATERTOWN, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain
Institutional Investors of Neumora Therapeutics, Inc. (NASDAQ:NMRA) Must Be Disappointed After Last Week's 14% Drop
Key Insights Given the large stake in the stock by institutions, Neumora Therapeutics' stock price might be vulnerable to their trading decisions 52% of the business is held by the top 4 shareholder
We're Hopeful That Neumora Therapeutics (NASDAQ:NMRA) Will Use Its Cash Wisely
Analysts Offer Insights on Healthcare Companies: Qiagen (QGEN), Innate Pharma SA (OtherIPHYF) and Neumora Therapeutics, Inc. (NMRA)
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) fell sharply during Monday's session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic d
Neumora Therapeutics Shares 15% Plummet As FDA Halts NMRA-266 Phase 1 Trial
Why Is Neurology Focused-Neumora Therapeutics Shares Trading Lower On Monday?
Neumora Therapeutics Inc (NASDAQ:NMRA) shares plummeted after the FDA placed a clinical hold on the company's Phase 1 trial of NMRA-266.NMRA-266 is a positive allosteric modulator (PAM) of the M4 musc
Sector Update: Health Care Stocks Advance Premarket Monday
Health care stocks were advancing in premarket activity Monday as the Health Care Select Sector SPDR Fund (XLV) was up 0.6% and the iShares Biotechnology ETF (IBB) was 0.3% higher recently. Neumora Th
Sector Update: Health Care
Health care stocks rose in premarket activity Monday as the Health Care Select Sector SPDR Fund (XLV) was up 0.6% and the iShares Biotechnology ETF (IBB) was 0.3% higher recently. Neumora Therapeutics
NXPL, MGRM and OCX Among Pre-market Losers
Marinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining over 200 points on Monday. Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) fell sharply in today's pre-market trading a
Analysis
Price Target
No Data
